| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11478450 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(15 years from now) | |
| US11241416 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(15 years from now) | |
| US10987341 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(15 years from now) | |
| US11826352 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(15 years from now) | |
Radicava Ors is owned by Mitsubishi Tanabe.
Radicava Ors contains Edaravone.
Radicava Ors has a total of 4 drug patents out of which 0 drug patents have expired.
Radicava Ors was authorised for market use on 12 May, 2022.
Radicava Ors is available in suspension;oral dosage forms.
Radicava Ors can be used as treatment of amyotrophic lateral sclerosis.
The generics of Radicava Ors are possible to be released after 01 November, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-144) | May 12, 2029 |
| New Product(NP) | May 12, 2025 |
Drugs and Companies using EDARAVONE ingredient
Market Authorisation Date: 12 May, 2022
Treatment: Treatment of amyotrophic lateral sclerosis
Dosage: SUSPENSION;ORAL
How can I launch a generic of RADICAVA ORS before it's drug patent expiration?
More Information on Dosage
RADICAVA ORS family patents
